Klivira
Request demo

Streamlining Aetna Orilissa Prior Authorization Workflows

Navigating Aetna Orilissa prior authorization requires precise understanding of payer-specific requirements and submission protocols. Klivira streamlines this complex process, integrating directly with Aetna's systems to accelerate approvals for elagolix.

For revenue cycle directors and prior authorization coordinators, managing high-volume specialty drug PAs like Orilissa presents significant operational challenges. This guide details the specific pathways and criteria for securing Aetna prior authorizations for Orilissa, an oral GnRH antagonist used for endometriosis and uterine fibroids.

Orilissa Under Aetna's Pharmacy Benefit

Orilissa (elagolix) is an oral gonadotropin-releasing hormone (GnRH) receptor antagonist indicated for the management of moderate to severe pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids. As an oral specialty medication, Orilissa typically falls under Aetna's pharmacy benefit, which is administered by CVS Caremark. This classification dictates the specific prior authorization channels and policy application.

Aetna Prior Authorization Submission Channels for Orilissa

For pharmacy-benefit medications like Orilissa, Aetna routes prior authorization requests through its PBM, CVS Caremark. Submissions for retail pharmacy benefits are predominantly handled via electronic prior authorization (ePA) partners such as CoverMyMeds or Surescripts. For mail-order or case-managed scenarios, providers may utilize CVS Caremark's direct provider portal. While Aetna supports X12 278 transactions for medical benefit precertifications, this channel is not typically applicable for oral pharmacy-benefit drugs.

Aetna Clinical Policy Criteria for Orilissa

Aetna's medical necessity criteria for pharmacy-benefit drugs, including specialty medications like Orilissa, are published as Clinical Policy Bulletins (CPBs) in the public Aetna CPB library. These CPBs outline specific requirements such as diagnosis confirmation, documented prior therapies (step therapy), duration limits, and other clinical indicators. Revenue cycle teams must consult the most current, applicable CPB to ensure all documentation aligns with Aetna's specific criteria for elagolix.

Common Denial Reasons for Specialty Drugs with Aetna

  • Medical necessity not met or insufficient documentation to support criteria outlined in the CPB.
  • Failure to document required step therapy or prior therapies as mandated by Aetna's clinical policy.
  • Off-label use without supporting compendium evidence, if applicable.
  • Benefit exclusion or policy limitations not covered by the member's plan.
  • Incomplete or untimely submission of clinical information.

Navigating Aetna's Appeal Process for Orilissa Denials

Should an Aetna Orilissa prior authorization request be denied, Aetna provides a structured appeal pathway. This typically includes levels such as reconsideration, peer-to-peer review with a plan medical director, and formal appeal. Expedited appeal pathways are available for urgent care needs. Adherence to timely-filing windows, which vary by line of business and state regulations, is critical. External review eligibility follows state external-review program rules for commercial lines and federal Independent Review Organization (IRO) processes for Medicare Advantage.

Automating Aetna Orilissa Prior Authorization with Klivira

Klivira's platform integrates with EMRs and payer portals, including Aetna's systems, to automate the prior authorization lifecycle for drugs like Orilissa. By extracting patient data, populating forms, and managing submission and status checks electronically, Klivira reduces manual workload and accelerates decision times. This automation helps mitigate common denial reasons by ensuring comprehensive and accurate submissions, aligning with Aetna's specific clinical criteria and submission channel requirements.

Frequently asked questions

What is the primary channel for Aetna Orilissa prior authorization submissions?

As Orilissa typically falls under Aetna's pharmacy benefit, prior authorization requests are primarily submitted via ePA partners like CoverMyMeds or Surescripts for retail prescriptions. For mail-order scenarios, the CVS Caremark direct provider portal is generally used.

How does Aetna publish its clinical criteria for drugs like Orilissa?

Aetna publishes its medical necessity criteria for pharmacy-benefit drugs, including specialty medications such as Orilissa, within its public Clinical Policy Bulletins (CPBs). These CPBs contain detailed requirements, including potential step therapy protocols and diagnostic criteria.

Does Aetna utilize step therapy for specialty medications such as Orilissa?

Yes, Aetna often incorporates step therapy protocols for specialty medications. These requirements are typically documented within the applicable Clinical Policy Bulletins (CPBs) for the specific drug and condition, requiring documentation of prior tried and failed therapies.

What are typical turnaround times for Aetna pharmacy benefit PAs?

Turnaround times for Aetna pharmacy benefit PAs are governed by state-mandated minimums and NCQA Utilization Management accreditation standards. For Aetna's Medicare Advantage and Medicaid managed care lines, CMS-0057-F mandates 72-hour decisions for standard PA and 24-hour for expedited PA requests, on a phased compliance timeline.

What are common reasons for Aetna Orilissa prior authorization denials?

Common denial reasons for Orilissa with Aetna include insufficient documentation to meet medical necessity criteria, failure to comply with step therapy requirements, or submission for off-label use without adequate compendium support. Benefit exclusions under the member's specific plan can also lead to denials.

Related coverage

Other orilissa prior authorization by payer

Other orilissa prior authorization by specialty

Ready to automate prior auth for this drug?

See how Klivira automates prior authorizations for your team.

Request a demo